Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...
The biotechnology and drug manufacturing market continues to give investors a hit-and-miss. Bears are betting heavily against Hims and Hers (HIMS), holding a short interest of 28.31%. On May 21, Hims ...
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
A new experiment is seeking to validate whether living cancer samples can be prepared, operated, monitored, and recovered ...
The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
ASCO is just around the corner, and as usual, there is a fertile crop of high-profile clinical trials to look out for among the late-breaker presentations. To follow – and in no particular order - are ...
The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results